NCT02014558 2024-12-03
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Astellas Pharma Inc
Phase 1/2 Completed
Astellas Pharma Inc
BeiGene
Children's Oncology Group
Medical College of Wisconsin
Johns Hopkins University
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Pfizer